Nuclear Medicine Communications最新文献

{"title":"Measuring glomerular filtration rate by transdermal detection of fluorescence: moving away from radioactivity and towards slope-only glomerular filtration rate?","authors":"A Michael Peters","doi":"10.1097/MNM.0000000000002219","DOIUrl":"https://doi.org/10.1097/MNM.0000000000002219","url":null,"abstract":"","PeriodicalId":19708,"journal":{"name":"Nuclear Medicine Communications","volume":"47 11","pages":"1221-1223"},"PeriodicalIF":1.4,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149128272","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Publication trends and knowledge structure of prostate-specific membrane antigen radioligand therapy for prostate cancer: a bibliometric analysis, 2015-2025.","authors":"Hao Long, Xu-Hua Qiao, Xu Li, Xiang-Jun Kong, Qin-Wen Liu","doi":"10.1097/MNM.0000000000002193","DOIUrl":"https://doi.org/10.1097/MNM.0000000000002193","url":null,"abstract":"<p><strong>Objective: </strong>To characterize publication growth, modality trends, and thematic evolution in prostate-specific membrane antigen (PSMA) radioligand therapy (RLT) for prostate cancer from 2015 to 2025, emphasizing beta-emitting RLT, targeted alpha therapy, and dosimetry-related terminology.</p><p><strong>Methods: </strong>The Web of Science Core Collection was searched using a prespecified topic strategy. A fixed bibliographic snapshot was exported on 1 January 2026, covering records through 31 December 2025. English-language articles and reviews were included. After screening and postexport cleaning, 908 publications underwent bibliometric analysis using bibliometrix, keyword mapping, and reference co-citation analysis. Therapeutic modality was assigned by deterministic text mining of titles, abstracts, and keywords with a prespecified alpha-priority rule; dual-label analyses assessed alpha/beta co-mentioning. Dosimetry-related terminology was identified using prespecified dictionaries. Two reviewers independently assessed modality in a random sample of 200 records.</p><p><strong>Results: </strong>Annual output increased from four publications in 2015 to 199 in 2025, although 2025 counts should be interpreted cautiously because of possible indexing delay. Under the primary classification, beta-emitting RLT predominated (698/908, 76.9%), whereas alpha-therapy-related publications accounted for 193/908 (21.3%). Under dual labeling, 149/908 publications (16.4%) co-mentioned alpha- and beta-based approaches. Dosimetry-related terminology increased over time and stabilized at approximately one-third of annual output after 2020. Inter-reviewer agreement was nearly perfect (kappa, 0.947-0.949).</p><p><strong>Conclusion: </strong>The PSMA RLT literature expanded rapidly and remained dominated by beta-emitting therapy, with increasing alpha-therapy activity and broader incorporation of dosimetry-related terminology. These bibliometric findings characterize publication-level trajectories in PSMA RLT research and suggest priorities for standardized reporting, scalable dosimetry, and prospective treatment-optimization studies.</p>","PeriodicalId":19708,"journal":{"name":"Nuclear Medicine Communications","volume":"47 11","pages":"1231-1241"},"PeriodicalIF":1.4,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149128259","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical assessment before PET/computed tomography: frequency and diagnostic impact.","authors":"Mohammed A M Alqahtani, Yuki Arita, Walter Noordzij, Thomas C Kwee","doi":"10.1097/MNM.0000000000002195","DOIUrl":"10.1097/MNM.0000000000002195","url":null,"abstract":"<p><strong>Objective: </strong>To investigate how often referring physicians perform history taking and physical examination before PET/computed tomography (PET/CT) referral, and whether their absence influences clinical reasoning quality or diagnostic yield.</p><p><strong>Methods: </strong>Patients undergoing PET/CT at a tertiary academic hospital were asked whether their referring physician had conducted history taking and physical examination before referral. Associations between omission of clinical assessment and clinical reasoning quality or PET/CT positivity (defined as PET/CT findings relevant to the clinical indication) were analyzed using multivariable regression.</p><p><strong>Results: </strong>Among 288 patients (median age: 66 years; 54% male), history taking was omitted in 18.2% and physical examination in 47.7%. For history taking, only referrals from pulmonology were significantly more likely to include history taking [odds ratio (OR): 4.708, P  = 0.033]. For physical examination, referrals from residents were more likely to include physical examination (OR: 2.355, P  = 0.022), as were surgical departments (OR: 8.527, P  = 0.030), requests for new clinical complaints (OR: 2.303, P  = 0.008), and total-body PET/CT scans (OR: 1.870, P  = 0.037), whereas urology referrals were less likely (OR: 0.019, P  = 0.008). Neither omission of history taking nor physical examination was associated with clinical reasoning quality or PET/CT positivity (all P  > 0.15).</p><p><strong>Conclusion: </strong>A relevant proportion of patients referred for PET/CT did not receive history taking or physical examination. While omission of these assessments did not appear to affect the clinical reasoning quality of the referring physicians or PET/CT yield, it may limit the contextual information available for interpreting imaging results.</p>","PeriodicalId":19708,"journal":{"name":"Nuclear Medicine Communications","volume":" ","pages":"1242-1248"},"PeriodicalIF":1.4,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148252538","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Radiolabeling and physicochemical characterization of terbium-161 DOTATATE.","authors":"Karan S Tanwar, Viraj V Sawant, Dinesh Rawat, Vivekanand Dubey, Abdul W Shaikh, Pooja Dwivedi, Indraja Dev, Sayak Choudhury, Archi Agrawal","doi":"10.1097/MNM.0000000000002201","DOIUrl":"10.1097/MNM.0000000000002201","url":null,"abstract":"<p><strong>Aim: </strong>To standardize the in-house radiolabeling procedure of [ 161 Tb]Tb-DOTATATE and to assess its physicochemical characteristics to facilitate the clinical application of somatostatin receptor-targeted radionuclide therapy.</p><p><strong>Methods: </strong>[ 161 Tb]Tb-DOTATATE was prepared by reconstituting DOTATATE in sodium acetate buffer (pH 4.5), along with ascorbic acid as a radio-stabilizer. The mixture was then incubated for 1 h at 100 °C. The radiochemical yield and radiochemical purity (RCP) of the final product were determined using radio-thin-layer chromatography (TLC) and radio-HPLC. Radionuclide identification was confirmed by high-purity germanium (HPGe) spectroscopy. In addition, the labeled product partition coefficient (log Po/w) and in-vitro plasma protein binding (PPB) were also tested. The in-vitro stability of the product was studied in saline and human serum using instant thin layer chromatography (ITLC) methods for up to 7 days.</p><p><strong>Result: </strong>Heating time affected the radiolabeling yield, which was greater than 99% at 1 h and 40% at 30 min in a dry bath. The RCP obtained was greater than 99% as measured by the radio TLC scanner using the ITLC method. HPGe spectroscopy confirmed the radionuclide identity. The radiolabeled product exhibits good hydrophilicity, acceptable PPB, and stable in-vitro behavior in both saline and human serum for up to 7 days.</p><p><strong>Conclusion: </strong>The radiolabeling protocol produced high-quality, reproducible [ 161 Tb]Tb-DOTATATE with excellent physicochemical properties. This validates the feasibility of in-house production of [ 161 Tb]Tb-DOTATATE and provides a basis for future preclinical and clinical research into its therapeutic potential.</p>","PeriodicalId":19708,"journal":{"name":"Nuclear Medicine Communications","volume":" ","pages":"1224-1230"},"PeriodicalIF":1.4,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148397255","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Diagnostic value of integrated 18 F-fluorodeoxyglucose PET/MRI in initial staging and recurrence detection of Ewing sarcoma.","authors":"Marcel Alexander Drews, Aleksandar Milosevic, Sebastian Zensen, Marcel Opitz, Lale Umutlu, Wolfgang Peter Fendler, Michael Forsting, Ken Herrmann, Uta Dirksen, Benedikt Michael Schaarschmidt","doi":"10.1097/MNM.0000000000002196","DOIUrl":"10.1097/MNM.0000000000002196","url":null,"abstract":"<p><strong>Objectives: </strong>Ewing sarcoma (EwS) is the second most common malignant bone tumour in children and adolescents. Due to its highly aggressive nature, rapid and accurate initial diagnosis as well as reliable recurrence detection are essential for treatment planning. Standard diagnostic work-up includes MRI for local tumour assessment and whole-body MRI or 18 F-fluorodeoxyglucose-PET-computed tomography ( 18 F-FDG-PET/CT) for metastatic evaluation. 18 F-FDG-PET/MRI combines the soft-tissue contrast of MRI with the metabolic information of PET while reducing radiation exposure. As data on PET/MRI in EwS are limited, we assessed its accuracy in primary staging and recurrence detection in a high-volume sarcoma center.</p><p><strong>Methods: </strong>In this monocentric retrospective study, whole-body 18 F-FDG-PET/MRI scans of 38 therapy-naïve EwS patients were analyzed for local and distant tumor spread. Additional scans of 43 EwS patients were evaluated for recurrence. PET/MRI findings were compared with whole-body MRI alone and a composite reference standard by two independent readers. Sensitivity and specificity were calculated.</p><p><strong>Results: </strong>PET/MRI showed higher sensitivity than MRI alone for lymph node metastases in both initial (91.7% vs. 25%) and follow-up staging (100% vs. 33.3%), with equally high specificity (96.8%). PET/MRI also showed slightly higher sensitivity for soft-tissue recurrence (100% vs. 90%). No difference between PET/MRI and MRI was found for bone or lung lesions, although both were less sensitive than chest CT (60% vs. 100%).</p><p><strong>Conclusion: </strong>18 F-FDG-PET/MRI is a feasible tool for both primary and follow-up imaging of EwS, providing excellent local tumor evaluation and high sensitivity for metastases and recurrence. However, chest CT remains necessary for small lung lesion detection.</p>","PeriodicalId":19708,"journal":{"name":"Nuclear Medicine Communications","volume":" ","pages":"1249-1257"},"PeriodicalIF":1.4,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148252563","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Radiobiological comparison of holmium-166 and yttrium-90 for hepatocellular carcinoma treatment in vitro.","authors":"Justine Perrin, Carolline Ntihabose, Tijmen H de Wolf, Duschka Kleijn, Erik de Blois, Mark Konijnenberg, Antonia Denkova, Julie Nonnekens","doi":"10.1097/MNM.0000000000002190","DOIUrl":"10.1097/MNM.0000000000002190","url":null,"abstract":"<p><p>Radioembolization for hepatocellular carcinoma uses microspheres radiolabeled with yttrium-90 or holmium-166, yet their radiobiological effectiveness has not been directly compared, leaving radionuclide selection uninformed by biological considerations. We assessed the survival and DNA damage induction following 1.5 or 2.5 Gy of [ 166 Ho]Ho-DOTA or [ 90 Y]Y-DOTA delivered over 24 h on three human hepatocellular carcinoma cell lines. Both radionuclides led to a similar, dose-dependent reduction of survival in all cell lines, with a modest but nonsignificant trend towards increased toxicity for [ 166 Ho]Ho-DOTA. Notably, [ 166 Ho]Ho-DOTA induced fewer, but larger DNA damage foci at earlier time points during irradiation, suggesting subtle differences in damage complexity or repair kinetics. These findings suggest that when delivering the same absorbed dose over 24 h, [ 166 Ho]Ho-DOTA and [ 90 Y]Y-DOTA demonstrate comparable cytotoxicity in vitro . These findings imply that in clinical settings, additional factors such as total injected activity and microsphere composition and biodistribution likely exert greater influence on treatment efficacy than radionuclide choice alone.</p>","PeriodicalId":19708,"journal":{"name":"Nuclear Medicine Communications","volume":" ","pages":"1274-1280"},"PeriodicalIF":1.4,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13641249/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148157541","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A comparative assessment of [ 99m Tc] HYNIC-PSMA-11 scintigraphy in prostate cancer as a potential substitute for disease evaluation with [ 68 Ga] PSMA-11 PET/CT imaging.","authors":"Monika Hooda, Aditya P Sharma, Ankit Watts, Piyush Aggarwal, Ravimohan Mavuduru, Harmandeep Singh, Nandita Kakkar, Shrawan K Singh, Baljinder Singh","doi":"10.1097/MNM.0000000000002191","DOIUrl":"10.1097/MNM.0000000000002191","url":null,"abstract":"<p><strong>Objectives: </strong>This study evaluated if [ 99m Tc]HYNIC-prostate-specific membrane antigen (PSMA)-11 scintigraphy presents a clinically viable imaging alternative to [ 68 Ga]PSMA-11 PET/computed tomography (CT) for disease evaluation in prostate cancer (PC).</p><p><strong>Methods: </strong>In this prospective study, 106 patients diagnosed with prostate cancer were recruited. A total of 51 patients were assigned in the initial staging cohort and the remaining 55 patients in the re-staging cohort (comprising biochemical recurrence, metastatic castration-resistant prostate cancer, and metastatic hormone-sensitive prostate cancer). Imaging with [ 99m Tc] HYNIC-PSMA-11 was conducted within one week following [ 68 Ga]PSMA-11 PET/CT. Whole-body planar [ 99m Tc]HYNIC-PSMA-11 images were obtained at 2-, 4-h, and regional SPECT/CT at 3-h. A comparative detection efficiency of [ 99m Tc]HYNIC-PSMA-11 versus [ 68 Ga]PSMA-11 PET/CT was evaluated by consensus for the involved lesions/sites. A correlation analysis was carried out between maximum standardized uptake values of PSMA PET and percent quantitative lesion uptake values of PSMA SPECT.</p><p><strong>Results: </strong>[ 68 Ga]PSMA-11 PET/CT detected 896 metastatic lesions, where HYNIC-PSMA-11 detected 761 lesions, offering an overall sensitivity of 85%. The sensitivity of [ 99m Tc] HYNIC-PSMA-11 SPECT/CT was 100% for primary/visceral lesions, 92% for skeletal lesions, 75.3% for distant lymph nodes and 67.4% for locoregional lymph nodes. A substantial agreement ( κ = 0.78, P < 0.0001) was seen between two imaging modalities. UCSF Cancer of the Prostate Risk Assessment score based disease staging matched with the disease staging demonstrated by both the imaging techniques. A significant ( P < 0.01) correlation was seen between the quantitative parameters of the two techniques both for primary ( r = 0.96) and metastatic ( r = 0.79 for skeletal and r = 0.65 for lymph nodes) lesions.</p><p><strong>Conclusion: </strong>[ 99m Tc]HYNIC-PSMA-11 SPECT/CT offers a potentially viable and cost-effective substitute for PSMA-PET for disease staging, quantification and response assessment to PSMA-targeted radiotherapies.</p>","PeriodicalId":19708,"journal":{"name":"Nuclear Medicine Communications","volume":" ","pages":"1265-1273"},"PeriodicalIF":1.4,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148302637","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prediction of tumor radiation absorbed dose in radionuclide therapy based on the mean standardized uptake value from PET imaging.","authors":"José Willegaignon, Marcelo Tatit Sapienza","doi":"10.1097/MNM.0000000000002197","DOIUrl":"10.1097/MNM.0000000000002197","url":null,"abstract":"<p><p>Accurate estimation of tumor absorbed dose is essential for effective disease control in radionuclide therapy, but routine dosimetry is often limited by the need for multiple posttherapy imaging acquisitions. This study aimed to develop a simplified method to predict tumor absorbed doses in radionuclide therapy using pretherapy PET standardized uptake value (SUV) measurements. Tumor absorbed doses were estimated using the medical internal radiation dose formalism, PET SUV mean , and radionuclide physical and effective half-lives, assuming comparable tumor uptake between diagnostic and therapeutic radiopharmaceuticals. A mathematical equation was derived to facilitate tumor dose estimation. For representative clinically administered activities, tumor absorbed doses per unit SUV mean were 1.84 ± 0.22, 1.07 ± 0.13, 0.58 ± 0.07, and 0.10 ± 0.01 Gy for the 68 Ga/ 90 Y, 124 I/ 131 I, 68Ga/ 177 Lu, and 68 Ga/ 225 Ac theranostic pairs, respectively. Tumor absorbed dose estimation showed a strong dependence on SUV mean and effective half-life, with good agreement between estimated values and previously reported dosimetric results. Although this simplified model does not replace full patient-specific dosimetry, it may provide a practical approach for pretherapy dose prediction. Further studies are required to validate and refine the proposed model.</p>","PeriodicalId":19708,"journal":{"name":"Nuclear Medicine Communications","volume":" ","pages":"1281-1287"},"PeriodicalIF":1.4,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148284093","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Parallel workflow for hospital-based 68Ga-prostate-specific membrane antigen PET: a practical operational experience.","authors":"Masanori Watanabe, Hiroshi Yamaguchi, Takahiro Toda, Yoshitaka Inui, Masanobu Saruta, Kiyoshi Takahara, Ryoichi Shiroki","doi":"10.1097/MNM.0000000000002200","DOIUrl":"https://doi.org/10.1097/MNM.0000000000002200","url":null,"abstract":"","PeriodicalId":19708,"journal":{"name":"Nuclear Medicine Communications","volume":"47 11","pages":"1288-1289"},"PeriodicalIF":1.4,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149128277","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prognostic value of baseline 18F-fluroodexoygloucose PET/computed tomography-derived maximum standardized uptake value and tumor bulk in pediatric Hodgkin lymphoma: a retrospective analysis: Retraction.","authors":"Nadia Nazir, Zeeshan Sikandar, Faiza Afzal, Aruba Nawaz Khattak, Anis Ur Rehman, Khalid Javed, Irfana Ishaq Sindhu","doi":"10.1097/MNM.0000000000002226","DOIUrl":"10.1097/MNM.0000000000002226","url":null,"abstract":"","PeriodicalId":19708,"journal":{"name":"Nuclear Medicine Communications","volume":"47 11","pages":"1290"},"PeriodicalIF":1.4,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149128308","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}